Iantrek's AlloSpan Canal makes way into US site evaluations

Iantrek is introducing AlloSpan™ Canal, a bio-reinforced canal restoration platform intended for trabecular intervention in glaucoma, and its US controlled release plan by way of US site evaluations. The company said in a news release the milestone represents a step toward commercialization and expansion of its Allo platform focused on natural outflow restoration.¹

A controlled US early access program is currently underway, with broader commercialization anticipated in 2027, according to the release.

AlloSpan Canal is designed to address limitations associated with existing approaches by combining nitinol-guided canaloplasty with biological reinforcement. According to the company, the platform aims to restore and maintain Schlemm’s canal without leaving synthetic hardware in the eye, offering an alternative to procedures that either provide temporary expansion or rely on permanent implants.¹

“The goal is to rehabilitate trabecular outflow, which is significantly diminished in patients with glaucoma, through a TM-sparing, minimally invasive approach that restores and maintains Schlemm’s canal,” said Sean Ianchulev, MD, MPH, professor of Ophthalmology at New York Eye and Ear and founder of Iantrek, in the release. “Bio-reinforced canaloplasty, as enabled by AlloSpan Canal, combines nitinol-based canal intervention with allogeneic biological scaffolding to achieve durable restoration of the canal in a way that is both structurally supportive and biologically integrated.”

The technology will be presented by Ianchulev at the 2026 Kelman Innovation Lecture during the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting.

Glaucoma is a leading cause of irreversible vision loss and is associated with impaired aqueous humor drainage and elevated intraocular pressure. Approximately 500,000 minimally invasive glaucoma surgery (MIGS) procedures are performed annually in the US targeting trabecular outflow, with existing approaches offering either transient canal expansion or permanent implants to maintain patency.¹

AlloSpan Canal incorporates a trabecular meshwork-sparing, nitinol-guided canaloplasty with placement of a retained scleral bio-implant composed of homologous tissue. The implant is intended to reinforce canal architecture and maintain outflow without synthetic materials. The system is described in the release as an FDA-registered, minimally manipulated, homologous use HCT/P and is aligned with an established Category I procedural code.

“For years, canal-based surgery has been constrained by a forced tradeoff between temporary and permanent procedural offerings. We believe that constraint is going away. Canal intervention is now positioned to evolve from a procedural trade-off into a durable, restorative treatment strategy,” said Adam Szaronos, CEO of Iantrek, in the release. “This unmet need is what AlloSpan Canal is designed to enable as we extend our bio-interventional approach to the primary outflow pathway.”

Following initial first-in-human cases conducted outside the United States, Iantrek said it is initiating a controlled early access program at select US clinical sites. The company plans to collect clinical data from these cases to inform surgeon experience, procedural refinement, and real-world performance ahead of a broader commercialization planned for 2027.¹

“We’ve had ways to dilate the canal and ways to scaffold it with hardware,” said Arkadiy Yadgarov, MD, in the release. “This is the first time I’ve seen an approach that dilates the canal and reinforces it biologically. Retaining canal restoration without synthetic hardware is a compelling concept and opens a new chapter for all surgeons performing angle surgery.”

Reference